Molecular Partners Statistics
Share Statistics
Molecular Partners has 36.87M
shares outstanding. The number of shares has increased by 11.13%
in one year.
| Shares Outstanding | 36.87M |
| Shares Change (YoY) | 11.13% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 10.79% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 119 |
| FTD / Avg. Volume | 1.08% |
Short Selling Information
The latest short interest is 51.17K, so 0.14% of the outstanding
shares have been sold short.
| Short Interest | 51.17K |
| Short % of Shares Out | 0.14% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 1.06 |
Valuation Ratios
The PE ratio is -2.72 and the forward
PE ratio is -1.87.
Molecular Partners's PEG ratio is
0.17.
| PE Ratio | -2.72 |
| Forward PE | -1.87 |
| PS Ratio | 29.53 |
| Forward PS | 1.2 |
| PB Ratio | 1.04 |
| P/FCF Ratio | -2.45 |
| PEG Ratio | 0.17 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Molecular Partners.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.31,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.31 |
| Quick Ratio | 14.31 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.04 |
| Interest Coverage | -2448.68 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $31,455.7 |
| Profits Per Employee | $-342,044.3 |
| Employee Count | 158 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 5.39% in the
last 52 weeks. The beta is 0.52, so Molecular Partners's
price volatility has been higher than the market average.
| Beta | 0.52 |
| 52-Week Price Change | 5.39% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 5.15 |
| Relative Strength Index (RSI) | 47.32 |
| Average Volume (20 Days) | 10,971 |
Income Statement
In the last 12 months, Molecular Partners had revenue of 4.97M
and earned -54.04M
in profits. Earnings per share was -1.59.
| Revenue | 4.97M |
| Gross Profit | 4.97M |
| Operating Income | -61.22M |
| Net Income | -54.04M |
| EBITDA | -51.65M |
| EBIT | -54.02M |
| Earnings Per Share (EPS) | -1.59 |
Full Income StatementBalance Sheet
The company has 63.87M in cash and 2.44M in
debt, giving a net cash position of 61.43M.
| Cash & Cash Equivalents | 63.87M |
| Total Debt | 2.44M |
| Net Cash | 61.43M |
| Retained Earnings | -246.29M |
| Total Assets | 158.53M |
| Working Capital | 143.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -59.25M
and capital expenditures -723K, giving a free cash flow of -59.97M.
| Operating Cash Flow | -59.25M |
| Capital Expenditures | -723K |
| Free Cash Flow | -59.97M |
| FCF Per Share | -1.76 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -1231.73% and -1087.38%.
| Gross Margin | 100% |
| Operating Margin | -1231.73% |
| Pretax Margin | -1087.34% |
| Profit Margin | -1087.38% |
| EBITDA Margin | -1039.18% |
| EBIT Margin | -1231.73% |
| FCF Margin | -1206.66% |
